BACKGROUND AND PURPOSE: Lombardia GENS is a multicentre prospective study aimed at diagnosing 5 single-gene disorders associated with stroke (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, Fabry disease, MELAS [mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes], hereditary cerebral amyloid angiopathy, and Marfan syndrome) by applying diagnostic algorithms specific for each clinically suspected disease METHODS: We enrolled a consecutive series of patients with ischemic or hemorrhagic stroke or transient ischemic attack admitted in stroke units in the Lombardia region participating in the project. Patients were defined as probable when presenting with stroke or transient ischemic attack of unknown etiopathogenic causes, or in the presence of <3 conventional vascular risk factors or young age at onset, or positive familial history or of specific clinical features. Patients fulfilling diagnostic algorithms specific for each monogenic disease (suspected) were referred for genetic analysis. RESULTS: In 209 patients (57.4±14.7 years), the application of the disease-specific algorithm identified 227 patients with possible monogenic disease. Genetic testing identified pathogenic mutations in 7% of these cases. Familial history of stroke was the only significant specific feature that distinguished mutated patients from nonmutated ones. The presence of cerebrovascular risk factors did not exclude a genetic disease. CONCLUSIONS: In patients prescreened using a clinical algorithm for monogenic disorders, we identified monogenic causes of events in 7% of patients in comparison to the 1% to 5% prevalence reported in previous series.

Clinical pregenetic screening for stroke monogenic diseases: results from Lombardia GENS registry / A. Bersano, H.S. Markus, S. Quaglini, E. Arbustini, S. Lanfranconi, G. Micieli, G.B. Boncoraglio, F. Taroni, C. Gellera, S. Baratta, S. Penco, L. Mosca, M. Grasso, P. Carrera, M. Ferrari, C. Cereda, G. Grieco, S. Corti, D. Ronchi, M. Teresa Bassi, L. Obici, E.A. Parati, A. Pezzini, M.L. De Lodovici, E.P. Verrengia, G. Bono, F. Mazucchelli, D. Zarcone, M.V. Calloni, P. Perrone, B.M. Bordo, A. Colombo, A. Padovani, A. Cavallini, S. Beretta, C. Ferrarese, C. Motto, E. Agostoni, G. Molini, F. Sasanelli, M. Corato, S. Marcheselli, M. Sessa, G. Comi, N. Checcarelli, M. Guidotti, D. Uccellini, E. Capitani, L. Tancredi, M. Arnaboldi, B. Incorvaia, C.S. Tadeo, L. Fusi, G. Grampa, G. Merlini, N. Trobia, G.P. Comi, M. Braga, P. Vitali, P. Baron, C. Grond-Ginsbach, L. Candelise. - In: STROKE. - ISSN 0039-2499. - 47:7(2016), pp. 1702-1709.

Clinical pregenetic screening for stroke monogenic diseases: results from Lombardia GENS registry

A. Bersano
Primo
;
S. Lanfranconi;G.B. Boncoraglio;S. Corti;D. Ronchi;G.P. Comi;P. Vitali;L. Candelise
Ultimo
2016

Abstract

BACKGROUND AND PURPOSE: Lombardia GENS is a multicentre prospective study aimed at diagnosing 5 single-gene disorders associated with stroke (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, Fabry disease, MELAS [mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes], hereditary cerebral amyloid angiopathy, and Marfan syndrome) by applying diagnostic algorithms specific for each clinically suspected disease METHODS: We enrolled a consecutive series of patients with ischemic or hemorrhagic stroke or transient ischemic attack admitted in stroke units in the Lombardia region participating in the project. Patients were defined as probable when presenting with stroke or transient ischemic attack of unknown etiopathogenic causes, or in the presence of <3 conventional vascular risk factors or young age at onset, or positive familial history or of specific clinical features. Patients fulfilling diagnostic algorithms specific for each monogenic disease (suspected) were referred for genetic analysis. RESULTS: In 209 patients (57.4±14.7 years), the application of the disease-specific algorithm identified 227 patients with possible monogenic disease. Genetic testing identified pathogenic mutations in 7% of these cases. Familial history of stroke was the only significant specific feature that distinguished mutated patients from nonmutated ones. The presence of cerebrovascular risk factors did not exclude a genetic disease. CONCLUSIONS: In patients prescreened using a clinical algorithm for monogenic disorders, we identified monogenic causes of events in 7% of patients in comparison to the 1% to 5% prevalence reported in previous series.
CADASIL; Fabry disease; MELAS syndrome; Marfan syndrome; cerebral amyloid angiopathy, familial; genetics; stroke
Settore MED/26 - Neurologia
Settore MED/03 - Genetica Medica
2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
STROKEAHA.115.012281.full for my air.pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 527.63 kB
Formato Adobe PDF
527.63 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Stroke-2016-Bersano-1702-9.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.31 MB
Formato Adobe PDF
1.31 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/398137
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 29
social impact